Health Care & Life Sciences » Biotechnology | Calithera Biosciences Inc.

Calithera Biosciences Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
-
-
-
-
25,955.00
22,254
Cost of Goods Sold (COGS) incl. D&A
281.00
361.00
404.00
297.00
-
-
Gross Income
281.00
361.00
404.00
297.00
-
-
SG&A Expense
12,097.00
21,360.00
32,415.00
38,037.00
55,276.00
79,030
EBIT
12,378.00
21,721.00
32,819.00
-
29,686.00
57,281
Non Operating Income/Expense
1.00
9.00
-
-
-
-
Pretax Income
12,377.00
21,712.00
32,644.00
38,004.00
27,826.00
54,629
Consolidated Net Income
12,377.00
21,712.00
32,644.00
38,004.00
27,826.00
54,629
Net Income
12,377.00
21,712.00
32,644.00
38,004.00
27,826.00
54,629
Net Income After Extraordinaries
12,377.00
21,712.00
32,644.00
38,004.00
27,826.00
54,629
Net Income Available to Common
12,377.00
21,712.00
32,644.00
38,004.00
27,826.00
54,629
EPS (Basic)
0.65
4.67
1.81
1.95
0.84
1.49
Basic Shares Outstanding
19,081.60
4,652.00
18,045.00
19,486.00
32,951.00
36,604
EPS (Diluted)
0.65
4.67
1.81
1.95
0.84
1.49
Diluted Shares Outstanding
19,081.60
4,652.00
18,045.00
19,486.00
32,951.00
36,604
EBITDA
12,097.00
21,360.00
32,415.00
38,037.00
29,321.00
56,776
Non-Operating Interest Income
-
-
175.00
330.00
1,860.00
2,652

About Calithera Biosciences

View Profile
Address
343 Oyster Point Boulevard
South San Francisco California 94080
United States
Employees -
Website http://www.calithera.com
Updated 07/08/2019
Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. It offers programs such as Pipeline, Glutaminase Inhibitor, and Arginase Inhibitor. The company was founded by James A.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.